A review on the therapeutic role of TKIs in case of CML in combination with epigenetic drugs
Chronic myeloid leukemia is a malignancy of bone marrow that affects white blood cells.
There is strong evidence that disease progression, treatment responses, and overall clinical …
There is strong evidence that disease progression, treatment responses, and overall clinical …
Novel therapeutic approaches in chronic myeloid leukemia
NÖ Yurttaş, AE Eşkazan - Leukemia Research, 2020 - Elsevier
The tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic
myeloid leukemia (CML) and BCR-ABL1 inhibitors form the mainstay of CML treatment …
myeloid leukemia (CML) and BCR-ABL1 inhibitors form the mainstay of CML treatment …
Chronic myeloid leukemia in the era of tyrosine kinase inhibitors: an evolving paradigm of molecularly targeted therapy
MAM Ali - Molecular diagnosis & therapy, 2016 - Springer
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, characterized by the
unrestrained expansion of pluripotent hematopoietic stem cells. CML was the first …
unrestrained expansion of pluripotent hematopoietic stem cells. CML was the first …
Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?
ML Mace, J Dahl, EJ Jabbour - Expert opinion on pharmacotherapy, 2015 - Taylor & Francis
Introduction: Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder
distinctly characterized by the presence of the Philadelphia chromosome, which results from …
distinctly characterized by the presence of the Philadelphia chromosome, which results from …
Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia
Simple Summary Chronic myeloid leukaemia (CML) is a type of blood cancer that is
currently well-managed with drugs that target cancer-causing proteins. However, a …
currently well-managed with drugs that target cancer-causing proteins. However, a …
Developing therapeutic approaches for chronic myeloid leukemia: a review
Modern clinical therapy of chronic myeloid leukemia (CML) with TKIs is highly efficacious in
most CML patients, while it is not remedial and generally confined due to intolerance or …
most CML patients, while it is not remedial and generally confined due to intolerance or …
Resistance to imatinib: mutations and beyond
P La Rosée, MW Deininger - Seminars in hematology, 2010 - Elsevier
Mechanisms of resistance to the tyrosine kinase inhibitor (TKI) imatinib had been modeled in
vitro even prior to the first reports of clinical resistance in patients with chronic myeloid …
vitro even prior to the first reports of clinical resistance in patients with chronic myeloid …
[PDF][PDF] The importance of mutational analyses in chronic myeloid leukaemia for treatment choice
H de Lavallade, A Kizilors - Eur Med J Oncol, 2016 - emjreviews.com
Since their introduction in 2001, tyrosine kinase inhibitors (TKIs) targeting BCR-ABL have
become the standard therapy for chronic myeloid leukaemia (CML). While allogeneic …
become the standard therapy for chronic myeloid leukaemia (CML). While allogeneic …
Therapy of chronic myeloid leukemia: twilight of the imatinib era?
E Trela, S Glowacki, J Błasiak - … Scholarly Research Notices, 2014 - Wiley Online Library
Chronic myeloid leukemia (CML) results from the clonal expansion of pluripotent
hematopoietic stem cells containing the active BCR/ABL fusion gene produced by a …
hematopoietic stem cells containing the active BCR/ABL fusion gene produced by a …
[PDF][PDF] Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence.
R Çiftçiler, IC Haznedaroglu - European Review for Medical & …, 2021 - europeanreview.org
Philadelphia (Ph*)/BCR-ABL1-positive chronic myeloid leukemia (CML) is a neoplastic
hematologic disorder, which is a functionally curable chronic disease via using tyrosine …
hematologic disorder, which is a functionally curable chronic disease via using tyrosine …